Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SYM021 + SYM023
- Development stage
- Phase 1
- Lead developer
- Symphogen
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
SYM021 + SYM023 is a **combination therapy** consisting of two fully human monoclonal antibodies: SYM021 (an anti-PD-1 antibody) and SYM023 (an anti-TIM-3 antibody). Both drugs are designed to block immune checkpoint pathways that cancer cells use to evade immune detection. By inhibiting these checkpoints (PD-1 and TIM-3), the combination aims to enhance the activity of T cells against cancer cells. SYM021 + SYM023 has been investigated in Phase 1b clinical trials for patients with advanced solid tumors and lymphomas, including biliary tract carcinoma and esophageal squamous cell carcinoma. The drugs are produced as recombinant proteins and administered intravenously. The combination is developed by Symphogen and has shown acceptable tolerability in early clinical studies, with immune-related adverse events being the most common. The efficacy signal in these early phase trials has not yet been established[1][3][5][9].
- Other names
- Sym021 + Sym023anti-PD-1 + anti-TIM-3
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)HAVCR2 (T cell immunoglobulin and mucin domain-containing protein 3)
Beyond the preview
Go deeper on SYM021 + SYM023.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SYM021 + SYM023.